Offices:
Hellerup
Average round investment:
13.66M USD
Novo A/S is a private limited liability company fully owned by the Novo Nordisk Foundation.
Besides being the major shareholder in the Novo Group companies, Novo A/S provides seed (Novo Seeds) and venture capital (Novo Ventures) to development stage companies and takes significant ownership positions in well-established companies, within life science, as well as manages a broad portfolio of financial assets.
We tracked 8 Nordic investments.
You need an account to access this feature.
Login or create one from
here.
(it takes 20 seconds)
Novo A/S investments breakdown analysis:
You need an account to access this feature.
Login or create one from
here.
(it takes 20 seconds)
Novo A/S mostly invests with:
You need an account to access this feature.
Login or create one from
here.
(it takes 20 seconds)
Investors with similar profile to Novo A/S:
| Investor | Criteria |
|---|
 Novo Seeds78% | - Range for average deal size: 10M - 20M USD
- Similar verticals: Biotech, Health services, Pharma
- Similar business models: B2B
- Common investees countries: Denmark
- Average number of deals per year: 2.5
- Active last 12 months: Yes
|
| Lundbeckfond Ventures 57% | - Similar verticals: Biotech, Health services, Pharma
- Similar business models: B2B
- Common investees countries: Denmark
- Average number of deals per year: 1.6
- Active last 12 months: Yes
|
| Index Ventures 57% | - Range for average deal size: 10M - 20M USD
- Similar verticals: Health services
- Similar business models: B2B
- Common investees countries: Denmark
- Average number of deals per year: 2.1
- Active last 12 months: Yes
|
| e.ventures 57% | - Range for average deal size: 10M - 20M USD
- Similar verticals: Health services
- Similar business models: B2B
- Common investees countries: Denmark
- Average number of deals per year: 1.6
- Active last 12 months: Yes
|
| Kurma Life Science Partners 56% | - Range for average deal size: 10M - 20M USD
- Similar verticals: Biotech, Pharma
- Similar business models: B2B
- Average number of deals per year: 1
|
 HealthCap56% | - Range for average deal size: 10M - 20M USD
- Similar verticals: Biotech, Health services
- Similar business models: B2B
- Average number of deals per year: 1.3
|
| Sunstone Life Science Ventures 56% | - Similar verticals: Biotech, Health services, Pharma
- Similar business models: B2B
- Common investees countries: Denmark
- Average number of deals per year: 1.2
- Active last 12 months: Yes
|
| Idinvest Partners 54% | - Range for average deal size: 10M - 20M USD
- Similar verticals: Pharma
- Similar business models: B2B
- Common investees countries: Denmark
- Average number of deals per year: 1.7
- Active last 12 months: Yes
|
 Ferd Capital52% | - Range for average deal size: 10M - 20M USD
- Similar verticals: Health services
- Similar business models: B2B
- Average number of deals per year: 1.3
- Active last 12 months: Yes
|
| Filip Engelbert 51% | - Range for average deal size: 10M - 20M USD
- Similar verticals: Health services
- Similar business models: B2B
- Average number of deals per year: 5
- Active last 12 months: Yes
|
